WhatA sourcing and processing platform that aggregates non-Chinese rare earth and alternative magnetic material supply for automotive and industrial customers hedging against Chinese export controls.
SignalChina's rare earth export controls to the EU have accelerated the push away from permanent magnet motors entirely, but many applications still need magnets — the supply chain diversification opportunity is massive and urgent.
Why NowChina has actively begun restricting rare earth exports to the EU, and the EU Industrial Accelerator Act is forcing supply chain localization, creating a regulatory-driven demand for alternative sourcing.
MarketEuropean and Indian automotive OEMs, wind turbine manufacturers, and industrial motor producers; $10B+ rare earth market with growing non-China demand; Gap: no trusted aggregator/marketplace for verified non-Chinese supply.
MoatLong-term offtake agreements with mines and processors outside China create supply lock-in; verified provenance data becomes a compliance asset under EU regulations.
CRISPR Delivery Platform for Solid Tumor TherapeuticsP7/10A biotech company focused specifically on solving the delivery problem for CRISPR-based cancer therapies, developing novel lipid nanoparticle or viral vector systems that can efficiently transport CRISPR payloads to solid tumors in vivo.
CRISPR Cancer Diagnostics for Undruggable MutationsP6/10A diagnostic platform that profiles patients' tumors for the specific genomic amplifications and mutations that CRISPR-shredding approaches can target, enabling oncologists to match patients to emerging CRISPR therapies.
Biotech Translation Tracker for Informed InvestorsC5/10A platform that tracks the real progress of preclinical and clinical-stage biotech breakthroughs — from lab results through delivery challenges, trial phases, and regulatory milestones — giving investors and patients an honest, hype-free assessment of how close therapies actually are to market.
Viral Vector Therapy Development Platform as ServiceC6/10A contract development platform that helps biotech startups and academic labs design, optimize, and manufacture viral vector (AAV/lentivirus) delivery systems for gene therapies, positioning as the picks-and-shovels play in gene therapy.
Automated Cost Guardrails for AI Agent OperationsP7/10A middleware layer that sits between AI agents and cloud/API services, enforcing hard spending limits, rate controls, and anomaly detection before any resource is consumed.
Prepaid Spending Caps for Cloud and API ServicesC6/10A financial wrapper service that lets developers provision hard-capped, prepaid budgets for cloud and API usage — once the balance hits zero, all calls stop instantly.